Key Points
- Tobin Juvenal sold 4,693 Castle Biosciences shares at an average $35.58 for a total of $166,976.94, trimming his position by 5.26% to 84,595 shares, as disclosed in an SEC filing.
- Castle Biosciences beat Q3 expectations with EPS of ($0.02) vs. consensus ($0.34) and revenue of $80.55M vs. $71.06M, and the stock carries a consensus Moderate Buy rating with an average price target of $37.43.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 4,693 shares of the firm's stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $35.58, for a total value of $166,976.94. Following the transaction, the insider directly owned 84,595 shares of the company's stock, valued at approximately $3,009,890.10. This trade represents a 5.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Castle Biosciences Trading Up 1.6%
Castle Biosciences stock opened at $38.49 on Tuesday. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $39.62. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -85.53 and a beta of 1.12. The business's fifty day simple moving average is $26.67 and its two-hundred day simple moving average is $21.66. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.32. The firm had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Castle Biosciences has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages have recently issued reports on CSTL. BTIG Research increased their price target on shares of Castle Biosciences from $32.00 to $38.00 and gave the company a "buy" rating in a report on Tuesday, November 4th. Robert W. Baird upped their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an "outperform" rating in a research report on Tuesday, November 4th. Zacks Research raised Castle Biosciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 20th. Weiss Ratings restated a "sell (d)" rating on shares of Castle Biosciences in a research note on Wednesday, November 19th. Finally, Wall Street Zen raised Castle Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.43.
View Our Latest Analysis on Castle Biosciences
Institutional Investors Weigh In On Castle Biosciences
Hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its stake in shares of Castle Biosciences by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 99,787 shares of the company's stock worth $2,272,000 after purchasing an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company's stock valued at $309,000 after buying an additional 655 shares during the period. Envestnet Asset Management Inc. increased its holdings in Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company's stock valued at $1,439,000 after buying an additional 707 shares during the last quarter. Inspire Investing LLC increased its holdings in Castle Biosciences by 4.0% during the third quarter. Inspire Investing LLC now owns 19,887 shares of the company's stock valued at $453,000 after buying an additional 770 shares during the last quarter. Finally, CWM LLC raised its position in Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company's stock worth $44,000 after acquiring an additional 853 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
